Biopharmaceutical company Telix Pharmaceuticals
(ASX:TLX) has entered into a strategic collaboration agreement with GenesisCare, the largest private provider of oncology services in Australia and Europe.
Firstly, GenesisCare and Telix have established a preferred clinical provider relationship for running radiation oncology studies in Australia for the inclusion of patients into Telix’s global multi-centre trials in neuro-oncology and urologic oncology.
Secondly, they will partner to deliver compassionate use access to Telix’s glioblastoma therapy program across its patient network.
Finally, they will jointly explore the commercial potential of Telix’s products in China.
Shares in Telix Pharmaceuticals
(ASX:TLX) closed 3.75 per cent lower to 77 cents.
